Robert Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, shared on X:

“Myeloma Paper of the Day: Study of immune fitness and teclistamab finds responders had higher baseline total T-cell counts, lower Tregs, fewer T-cells expressing co-inhibitory receptors, less soluble BCMA, and T-cell profile with more cytolytic potential.”

Proceed to the article.
Source: Robert Orlowski/X

Myeloma, also known as multiple myeloma, is a type of cancer that affects plasma cells, a type of white blood cell found in the bone marrow. Plasma cells are crucial for producing antibodies that help fight infection. In myeloma, the abnormal growth of plasma cells leads to the production of non-functional antibodies, which can cause various health problems. Symptoms of myeloma can include bone pain, fractures, anemia, kidney dysfunction, and increased susceptibility to infections. The disease is often diagnosed through blood tests, imaging, and bone marrow biopsies. Treatment options may include chemotherapy, targeted therapy, immunotherapy, stem cell transplants, and other approaches. Myeloma is generally considered incurable, but with advances in treatments, it can often be managed for extended periods.